Title	Publication Date	Language	Citations
Neurological Complications Associated With Anti–Programmed Death 1 (PD-1) Antibodies	2017/10/01	English	214
Assessment of Systemic Delivery of rAAVrh74.MHCK7.micro-dystrophin in Children With Duchenne Muscular Dystrophy	2020/09/01	English	211
Clinical Correlations With Lewy Body Pathology inLRRK2-Related Parkinson Disease	2015/01/01	English	211
Safety and Clinical Effects of Mesenchymal Stem Cells Secreting Neurotrophic Factor Transplantation in Patients With Amyotrophic Lateral Sclerosis	2016/03/01	English	211
Outcomes and Risk Factors Associated With SARS-CoV-2 Infection in a North American Registry of Patients With Multiple Sclerosis	2021/06/01	English	209
Genome-wide Pleiotropy Between Parkinson Disease and Autoimmune Diseases	2017/07/01	English	209
Evaluation of Tau Imaging in Staging Alzheimer Disease and Revealing Interactions Between β-Amyloid and Tauopathy	2016/09/01	English	209
Phase 3 Trial of Flutemetamol Labeled With Radioactive Fluorine 18 Imaging and Neuritic Plaque Density	2015/03/01	English	207
Prevalence, Determinants, and Effect on Quality of Life of Freezing of Gait in Parkinson Disease	2014/07/01	English	207
Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age	2015/09/01	English	205
Serum Brain-Derived Neurotrophic Factor and the Risk for Dementia	2014/01/01	English	203
Safety and Efficacy of Focused Ultrasound Thalamotomy for Patients With Medication-Refractory, Tremor-Dominant Parkinson Disease	2017/12/01	English	203
Association Between Anticholinergic Medication Use and Cognition, Brain Metabolism, and Brain Atrophy in Cognitively Normal Older Adults	2016/06/01	English	201
Randomized Clinical Trial of 3 Types of Physical Exercise for Patients With Parkinson Disease	2013/02/01	English	201
Assessment of Racial Disparities in Biomarkers for Alzheimer Disease	2019/03/01	English	201
Fingolimod for the Treatment of Intracerebral Hemorrhage	2014/09/01	English	199
Long-term Clinical Outcome of Fetal Cell Transplantation for Parkinson Disease	2014/01/01	English	197
Association of Autoimmune Encephalitis With Combined Immune Checkpoint Inhibitor Treatment for Metastatic Cancer	2016/08/01	English	197
Association of In Vivo [18F]AV-1451 Tau PET Imaging Results With Cortical Atrophy and Symptoms in Typical and Atypical Alzheimer Disease	2017/04/01	English	193
Efficacy and Safety of Rituximab Therapy in Neuromyelitis Optica Spectrum Disorders	2016/11/01	English	193
Serial Anti–Myelin Oligodendrocyte Glycoprotein Antibody Analyses and Outcomes in Children With Demyelinating Syndromes	2020/01/01	English	193
TREM2Variant p.R47H as a Risk Factor for Sporadic Amyotrophic Lateral Sclerosis	2014/04/01	English	193
Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum	2021/12/01	English	192
Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti–α-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease	2018/10/01	English	192
Clinical Outcomes of Escalation vs Early Intensive Disease-Modifying Therapy in Patients With Multiple Sclerosis	2019/05/01	English	190
Association ofMTORMutations With Developmental Brain Disorders, Including Megalencephaly, Focal Cortical Dysplasia, and Pigmentary Mosaicism	2016/07/01	English	189
Cerebrovascular Effects of Apolipoprotein E	2013/04/01	English	187
Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations	2020/04/01	English	186
Modification of the Relationship of the Apolipoprotein E ε4 Allele to the Risk of Alzheimer Disease and Neurofibrillary Tangle Density by Sleep	2013/12/01	English	185
Efficacy of Home-Based Telerehabilitation vs In-Clinic Therapy for Adults After Stroke	2019/09/01	English	185